Please assess the completion status of the following clinical trial:

Trial Title: Study of Single Dose GHB16L2 Trivalent Influenza Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female volunteers, 18-60 years~* Seronegative for one or two of the applied vaccine strains~* Low antibody titres for H1N1v~* Written informed consent to participate in this study~* For female volunteers of childbearing potential, provision of a history and current use of reliable contraceptive practices~Exclusion Criteria:~* Acute febrile illness (\>37.3°C)~* Signs of acute or chronic upper or lower tract respiratory illnesses~* History of severe atopy~* Seasonal influenza vaccination in 2008/2009 and/or later seasons and/or pandemic influenza vaccination at any time~* Fever ≥38.0°C in the time period between the pre-screening visit and day 1~* Known increased tendency of nose bleeding~* Volunteers with clinically relevant abnormal paranasal anatomy~* Volunteers with clinically relevant abnormal laboratory values~* In female volunteers of childbearing potential, a positive urine pregnancy test~* Simultaneous treatment with immunosuppressive drugs incl. Corticosteroids (≥2 weeks) within 4 weeks prior to study medication application~* Clinically relevant history of renal, hepatic, GI, cardiovascular, haematological, skin, endocrine, neurological or immunological diseases~* History of leukaemia or cancer~* HIV or Hepatitis B or C seropositivity~* Volunteers who underwent rhino or sinus surgery, or surgery of another traumatic injury of the nose within 30 days prior to application of study medication~* Volunteers who have received antiviral drugs, treatment with immunoglobulins or blood transfusions, or an investigational drug within 4 weeks prior to study medication application~* Volunteers who have received anti-inflammatory drugs 2 days prior to study medication application~* Volunteers who are not likely to cope with the requirements of the study or with a significant physical or mental condition that may interfere with the completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- SPGNH buffer (Type: PLACEBO_COMPARATOR): SPGNH buffer administration by liquid nasal spray
- GHB16L2 (Type: EXPERIMENTAL): Dose level \~7.0 log10 fTCID50/strain/person

Based on this trial design, predict the completion outcome and termination type (if applicable).